182 related articles for article (PubMed ID: 31815095)
41. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
[TBL] [Abstract][Full Text] [Related]
42. Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.
Gambaro K; Quinn MC; Cáceres-Gorriti KY; Shapiro RS; Provencher D; Rahimi K; Mes-Masson AM; Tonin PN
BMC Cancer; 2015 Mar; 15():135. PubMed ID: 25886299
[TBL] [Abstract][Full Text] [Related]
43. BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
Kwon JS; Tinker AV; Hanley GE; Pansegrau G; Sun S; Carey MS; Schrader I
Gynecol Oncol; 2019 Mar; 152(3):459-464. PubMed ID: 30876489
[TBL] [Abstract][Full Text] [Related]
44. A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
Rashid MU; Naeemi H; Muhammad N; Loya A; Yusuf MA; Lubiński J; Jakubowska A; Hamann U
Hered Cancer Clin Pract; 2016; 14():14. PubMed ID: 27413415
[TBL] [Abstract][Full Text] [Related]
45. Inherited Mutations in Women With Ovarian Carcinoma.
Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ
JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728
[TBL] [Abstract][Full Text] [Related]
46. CT texture analysis in histological classification of epithelial ovarian carcinoma.
An H; Wang Y; Wong EMF; Lyu S; Han L; Perucho JAU; Cao P; Lee EYP
Eur Radiol; 2021 Jul; 31(7):5050-5058. PubMed ID: 33409777
[TBL] [Abstract][Full Text] [Related]
47. Mutated p53 in HGSC-From a Common Mutation to a Target for Therapy.
Saleh A; Perets R
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298679
[TBL] [Abstract][Full Text] [Related]
48. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
49. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
50.
Manchana T; Tantbirojn P; Pohthipornthawat N
Gynecol Oncol Rep; 2020 Aug; 33():100582. PubMed ID: 32529018
[TBL] [Abstract][Full Text] [Related]
51. Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer.
Pavanello M; Chan IH; Ariff A; Pharoah PD; Gayther SA; Ramus SJ
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086730
[TBL] [Abstract][Full Text] [Related]
52. Prevalence of
Ataseven B; Tripon D; Rhiem K; Harter P; Schneider S; Heitz F; Baert T; Traut A; Pauly N; Ehmann S; Plett H; Schmutzler RK; du Bois A
Geburtshilfe Frauenheilkd; 2020 Sep; 80(9):932-940. PubMed ID: 32905297
[No Abstract] [Full Text] [Related]
53. Improved survival in women with BRCA-associated ovarian carcinoma.
Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
[TBL] [Abstract][Full Text] [Related]
54. Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.
Fleury H; Communal L; Carmona E; Portelance L; Arcand SL; Rahimi K; Tonin PN; Provencher D; Mes-Masson AM
Genes Cancer; 2015 Sep; 6(9-10):378-398. PubMed ID: 26622941
[TBL] [Abstract][Full Text] [Related]
55. PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
Zhang W; Barger CJ; Eng KH; Klinkebiel D; Link PA; Omilian A; Bshara W; Odunsi K; Karpf AR
Oncotarget; 2016 Jul; 7(29):45352-45369. PubMed ID: 27322684
[TBL] [Abstract][Full Text] [Related]
56. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
57. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
58. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
59. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
